Clinical Practice Recommendations for the Treatment of Alport Syndrome: a Statement of the Alport Syndrome Research Collaborative

Overview

Journal Pediatr Nephrol

Specialties Nephrology
Pediatrics

Date 2012 Mar 31

PMID 22461141

Citations 59

Authors

Clifford E Kashtan

Jie Ding

Martin Gregory

Oliver Gross

Laurence Heidet

Bertrand Knebelmann

Michelle Rheault

Christoph Licht

Affiliations

Soon will be listed here.

Abstract

We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.

Citing Articles

Fenestrated Endothelial Cells across Organs: Insights into Kidney Function and Disease.

Mou X, Leeman S, Roye Y, Miller C, Musah S Int J Mol Sci. 2024; 25(16).

PMID: 39201792 PMC: 11354928. DOI: 10.3390/ijms25169107.

Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease.

Kohan D, Bedard P, Jenkinson C, Hendry B, Komers R Clin Sci (Lond). 2024; 138(11):645-662.

PMID: 38808486 PMC: 11139641. DOI: 10.1042/CS20240249.

A Novel Pathogenic Variant Joins the Dots in a Family with a Synchronous Diagnosis of Alport Syndrome and Polycystic Kidney Disease.

Graziani L, Minotti C, Carriero M, Bengala M, Lai S, Terracciano A Genes (Basel). 2024; 15(5).

PMID: 38790225 PMC: 11121527. DOI: 10.3390/genes15050597.

Alport syndrome and Alport kidney diseases - elucidating the disease spectrum.

Puapatanakul P, Miner J Curr Opin Nephrol Hypertens. 2024; 33(3):283-290.

PMID: 38477333 PMC: 10990029. DOI: 10.1097/MNH.0000000000000983.

Urinary Protein-Biomarkers Reliably Indicate Very Early Kidney Damage in Children With Alport Syndrome Independently of Albuminuria and Inflammation.

Rhode H, Luse A, Tautkus B, Nabity M, John-Kroegel U, Weigel F Kidney Int Rep. 2023; 8(12):2778-2793.

PMID: 38106579 PMC: 10719601. DOI: 10.1016/j.ekir.2023.09.028.

References

Gross O, Schulze-Lohoff E, Koepke M, Beirowski B, Addicks K, Bloch W . Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis. Nephrol Dial Transplant. 2004; 19(7):1716-23. DOI: 10.1093/ndt/gfh219. View

Rheault M, Kren S, Hartich L, Wall M, Thomas W, Mesa H . X-inactivation modifies disease severity in female carriers of murine X-linked Alport syndrome. Nephrol Dial Transplant. 2009; 25(3):764-9. PMC: 2902925. DOI: 10.1093/ndt/gfp551. View

Jais J, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A . X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males. J Am Soc Nephrol. 2000; 11(4):649-657. DOI: 10.1681/ASN.V114649. View

Ninichuk V, Gross O, Reichel C, Khandoga A, Pawar R, Ciubar R . Delayed chemokine receptor 1 blockade prolongs survival in collagen 4A3-deficient mice with Alport disease. J Am Soc Nephrol. 2005; 16(4):977-85. DOI: 10.1681/ASN.2004100871. View

Lane P, Steffes M, Fioretto P, MAUER S . Renal interstitial expansion in insulin-dependent diabetes mellitus. Kidney Int. 1993; 43(3):661-7. DOI: 10.1038/ki.1993.95. View

Jais J, Knebelmann B, Giatras I, Marchi M, Rizzoni G, Renieri A . X-linked Alport syndrome: natural history and genotype-phenotype correlations in girls and women belonging to 195 families: a "European Community Alport Syndrome Concerted Action" study. J Am Soc Nephrol. 2003; 14(10):2603-10. DOI: 10.1097/01.asn.0000090034.71205.74. View

Hogg R, Portman R, Milliner D, Lemley K, Eddy A, Ingelfinger J . Evaluation and management of proteinuria and nephrotic syndrome in children: recommendations from a pediatric nephrology panel established at the National Kidney Foundation conference on proteinuria, albuminuria, risk, assessment, detection, and.... Pediatrics. 2000; 105(6):1242-9. DOI: 10.1542/peds.105.6.1242. View

Gross O, Beirowski B, Koepke M, Kuck J, Reiner M, Addicks K . Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome. Kidney Int. 2003; 63(2):438-46. DOI: 10.1046/j.1523-1755.2003.00779.x. View

Elises J, Griffiths P, Hocking M, Taylor C, White R . Simplified quantification of urinary protein excretion in children. Clin Nephrol. 1988; 30(4):225-9. View

10.

Marrs J . Spironolactone management of resistant hypertension. Ann Pharmacother. 2010; 44(11):1762-9. DOI: 10.1345/aph.1P338. View

11.

Zeisberg M, Bottiglio C, Kumar N, Maeshima Y, Strutz F, Muller G . Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models. Am J Physiol Renal Physiol. 2003; 285(6):F1060-7. DOI: 10.1152/ajprenal.00191.2002. View

12.

Gross O, Koepke M, Beirowski B, Schulze-Lohoff E, Segerer S, Weber M . Nephroprotection by antifibrotic and anti-inflammatory effects of the vasopeptidase inhibitor AVE7688. Kidney Int. 2005; 68(2):456-63. DOI: 10.1111/j.1523-1755.2005.00423.x. View

13.

Seeman T, Pohl M, Misselwitz J, John U . Angiotensin receptor blocker reduces proteinuria independently of blood pressure in children already treated with Angiotensin-converting enzyme inhibitors. Kidney Blood Press Res. 2009; 32(6):440-4. DOI: 10.1159/000266478. View

14.

Ellis D, Moritz M, Vats A, Janosky J . Antihypertensive and renoprotective efficacy and safety of losartan. A long-term study in children with renal disorders. Am J Hypertens. 2004; 17(10):928-35. DOI: 10.1016/j.amjhyper.2004.06.014. View

15.

Lubrano R, Soscia F, Elli M, Ventriglia F, Raggi C, Travasso E . Renal and cardiovascular effects of angiotensin-converting enzyme inhibitor plus angiotensin II receptor antagonist therapy in children with proteinuria. Pediatrics. 2006; 118(3):e833-8. DOI: 10.1542/peds.2005-2053. View

16.

Ninichuk V, Gross O, Segerer S, Hoffmann R, Radomska E, Buchstaller A . Multipotent mesenchymal stem cells reduce interstitial fibrosis but do not delay progression of chronic kidney disease in collagen4A3-deficient mice. Kidney Int. 2006; 70(1):121-9. DOI: 10.1038/sj.ki.5001521. View

17.

Pochet J, Bobrie G, Landais P, Goldfarb B, Grunfeld J . Renal prognosis in Alport's and related syndromes: influence of the mode of inheritance. Nephrol Dial Transplant. 1989; 4(12):1016-21. View

18.

Webb N, Lam C, Shahinfar S, Strehlau J, Wells T, Gleim G . Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial. Nephrol Dial Transplant. 2011; 26(8):2521-6. DOI: 10.1093/ndt/gfq797. View

19.

Sayers R, Kalluri R, RODGERS K, Shield C, Meehan D, Cosgrove D . Role for transforming growth factor-beta1 in alport renal disease progression. Kidney Int. 1999; 56(5):1662-73. DOI: 10.1046/j.1523-1755.1999.00744.x. View

20.

Bekheirnia M, Reed B, Gregory M, McFann K, Shamshirsaz A, Masoumi A . Genotype-phenotype correlation in X-linked Alport syndrome. J Am Soc Nephrol. 2010; 21(5):876-83. PMC: 2865738. DOI: 10.1681/ASN.2009070784. View